BAM
KLRS

Belpointe Asset Management’s Kalaris Therapeutics KLRS Stock Holding History

Belpointe Asset Management’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$231K Hold
40,000
– – 0.01% 957
2025
Q4 		$338K Hold
40,000
– – 0.01% 791
2025
Q3 		$231K Buy
+40,000
New +$132K 0.01% 882

Other funds holding KLRS

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kalehua Capital Management Dallas, Texas $141M AUM
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Belpointe Asset Management's KLRS Position: Q1 2026 in Review

Belpointe Asset Management held its Kalaris Therapeutics (KLRS) position steady in Q1 2026 at 40,000 shares worth $231K. The position accounts for 0.01% of the portfolio, ranked #957.

Belpointe Asset Management first reported a position in KLRS in Q3 2025 and has held it in 3 quarters since. The position peaked at $338K in Q4 2025. 58 funds tracked by Wall St. Rank hold KLRS as of Q1 2026.

  • Belpointe Asset Management held 40,000 shares of Kalaris Therapeutics worth $231K as of Q1 2026.
  • Belpointe Asset Management left its Kalaris Therapeutics share count unchanged in Q1 2026.
  • Kalaris Therapeutics made up 0.01% of Belpointe Asset Management's portfolio in Q1 2026, its #957 holding.
  • Belpointe Asset Management first reported a position in Kalaris Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Belpointe Asset Management's Kalaris Therapeutics position peaked at $338K in Q4 2025.
  • 58 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q1 2026.

Based on Belpointe Asset Management's 13F filing for Q1 2026, filed 28 Apr 2026.